Find a
Transforming the Pharmaceutical Industry
through Innovation

News and Events


Galt Pharmaceuticals Introduces New Convenient Package Size for Insomnia Drug

September 24, 2019

ATLANTA (September 24, 2019) – Galt Pharmaceuticals announced the availability of a new convenient package size of 30 count bottles for Doral 15mg, making the insomnia treatment more accessible to pharmacies and patients across the country. 

According to a recent study by the University of Pennsylvania School of Medicine that was reported in Science Daily, one in four Americans experience acute insomnia each year. Although many medications are available, Doral offers an alternative that has FDA indications for all three symptoms associated with insomnia: difficulty falling asleep, difficulty maintaining sleep and early morning awakenings. The new bottle size offers pharmacies a more efficient way to dispense Doral. The bottles will be available through all major wholesalers: Cardinal Health, McKesson and AmerisourceBergen.

Doral 15mg was re-launched by Galt in 2016 and prescriptions are growing exponentially each month. Doral serves unmet needs for Americans suffering from insomnia who have not found relief with current medications on the market. 

“As more and more healthcare providers learn about Doral and try their patients on it for the first time, we want pharmacies to have a smaller package size so they aren’t taking a risk on stocking a full 100 count bottle for one prescription of 15 or 30 tablets,” said Barry Patel, Pharm.D., Galt CEO and Co-Founder. 

The 100-count bottle of Doral (Quazepam) will continue to be available and offers pharmacies value as demand for this insomnia treatment grows.

“This new package size will encourage both chain and independent pharmacists to stock Doral without the risk of excessive shelf inventory while this product continues to gain traction in the market,” said Taylor Froiland, Pharm.D., owner of Medmetrics Pharmacy, an independent pharmacy in Chandler, Arizona.

“We’ve built Galt as a pharmacist-centric company and are always thinking about how we can help independent pharmacies survive and thrive,” said Galt Co-Founder Galt Chairman Wade Smith, Pharm.D. “We have hundreds of partnerships with independent pharmacists across the U.S. We listened and learned that inventory control could make a positive impact on their businesses.”

Galt also adds value by teaming up with independent pharmacists to make its products accessible to patients regardless of insurance status through the Galt Direct Patient Assistance Program.


About Doral (Quazepam)

Doral (Quazepam) is indicated for the treatment of insomnia characterized by difficulty falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.

Important Safety Information (ISI)

Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death [see Warnings and Precautions (5.1), Drug Interactions (7)]. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.

Doral can produce daytime impairment, and this risk increases with dose and concomitant use of other CNS depressants. If insomnia worsens or fails to remit after 7 to 10 days of treatment, this might be indication of an underlying illness. Doral is contraindicated in patients with a known hypersensitivity to quazepam or other benzodiazepines, established or suspected sleep apnea, or chronic pulmonary insufficiency. Rare cases of severe anaphylactic reactions including angioedema and dyspnea have been reported. Complex behaviors, such as sleep driving or sleep eating, have been reported with the use of sedative-hypnotics. Immediately evaluate the onset of any new behavioral changes. Benzodiazepines may worsen depression, and appropriate precautions should be considered in at risk patients. For a full list of warnings and precautions, please refer to the full prescribing information.

Visit for more details and full prescribing information.

Share the resource:

Share on Facebook Share on Twitter Share on LinkedIn Share on Google Plus